A $20 Billion Sweet Spot in Biotech
This previous year demonstrated gainful for speculators in Incyte (NASDAQ: INCY) and Seattle Genetics (NASDAQ: SGEN). Conveniently beating the expansive market and biotech lists, these two medication producers hit the $20 billion valuation mark and are ready to keep developing…